Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells 7,973 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard Prins sold 7,973 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $20.30, for a total value of $161,851.90. Following the sale, the director directly owned 29,625 shares of the company’s stock, valued at $601,387.50. This represents a 21.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amphastar Pharmaceuticals Trading Down 2.2%

AMPH stock traded down $0.44 during mid-day trading on Wednesday, reaching $19.98. The company’s stock had a trading volume of 337,350 shares, compared to its average volume of 532,241. Amphastar Pharmaceuticals, Inc. has a 12 month low of $16.65 and a 12 month high of $31.26. The company has a current ratio of 2.40, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79. The business’s 50 day moving average price is $19.74 and its 200 day moving average price is $21.28. The company has a market cap of $849.95 million, a price-to-earnings ratio of 11.82, a price-to-earnings-growth ratio of 4.29 and a beta of 0.89.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.62 by $0.29. The firm had revenue of $183.90 million for the quarter, compared to analysts’ expectations of $179.92 million. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%. On average, equities research analysts predict that Amphastar Pharmaceuticals, Inc. will post 2.25 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP increased its position in shares of Amphastar Pharmaceuticals by 12.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock worth $39,726,000 after acquiring an additional 228,262 shares in the last quarter. TD Asset Management Inc lifted its position in Amphastar Pharmaceuticals by 1.6% in the 4th quarter. TD Asset Management Inc now owns 1,963,052 shares of the company’s stock valued at $52,571,000 after acquiring an additional 31,160 shares in the last quarter. State Street Corp boosted its stake in Amphastar Pharmaceuticals by 2.1% during the 4th quarter. State Street Corp now owns 1,531,786 shares of the company’s stock valued at $41,021,000 after purchasing an additional 31,044 shares during the last quarter. Fuller & Thaler Asset Management Inc. increased its holdings in Amphastar Pharmaceuticals by 3.0% during the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 1,394,463 shares of the company’s stock worth $37,344,000 after purchasing an additional 40,536 shares in the last quarter. Finally, Marshall Wace LLP raised its stake in shares of Amphastar Pharmaceuticals by 41.6% in the fourth quarter. Marshall Wace LLP now owns 1,237,284 shares of the company’s stock worth $33,134,000 after purchasing an additional 363,216 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Wall Street Analysts Forecast Growth

AMPH has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Zacks Research raised Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 21st. Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $21.00 to $20.00 and set a “neutral” rating on the stock in a research note on Friday, August 7th. Wells Fargo & Company increased their price target on Amphastar Pharmaceuticals from $19.00 to $20.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Finally, Bank of America reissued an “underperform” rating and issued a $20.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, June 29th. Six equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Amphastar Pharmaceuticals currently has an average rating of “Reduce” and an average target price of $22.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.